NXN: A Potential Drug Target for Cancer and Cellular Homeostasis

Target Name: NXN

NCBI ID: G64359

Content of Review Report on NXN Target / Biomarker

NXN

NXN: A Potential Drug Target for Cancer and Cellular Homeostasis

NXN (Nucleoredoxin) is a protein that is expressed in most tissues of the body and plays a critical role in the regulation of DNA replication, repair, and metabolism. It is a nucleosome-remodeling enzyme that helps ensure the proper structure of DNA in the cell nucleus, which is essential for the expression of genetic information.

NXN is also involved in the repair of DNA damage, which is a critical aspect of cellular homeostasis. Damaged DNA can no longer be replicated, and this can lead to a range of cellular responses, including cell death, senescence, and cancer. Therefore, NXN plays a crucial role in preventing the accumulation of DNA damage and promoting the repair of damaged DNA.

In addition to its role in DNA repair, NXN is also involved in the regulation of cell cycle progression. It helps to keep the cell cycle in check, ensuring that cells divide at a proper rate and that the cell infrastructure is maintained.

Given its involvement in so many cellular processes, NXN has become an attractive drug target for researchers. Many drugs that are currently in use, such as taxol, are known to inhibit the activity of NXN, which has led to the study of alternative targets for these drugs.

One potential target for NXN is the protein p53, which is a well-known tumor suppressor protein. p53 is a transcription factor that plays a critical role in regulating the expression of many genes, including those that are involved in cell growth and division.

Research has shown that NXN can interact with p53 and that inhibiting the activity of NXN can lead to the degradation of p53. This suggests that NXN may be a useful biomarker for the assessment of the effectiveness of drugs that target p53.

Another potential target for NXN is the protein histone H3, which is a component of the nucleosome. Histone H3 plays a critical role in the regulation of DNA replication and has been shown to interact with NXN.

Research has shown that NXN can interact with histone H3 and that inhibiting the activity of NXN can lead to the degradation of histone H3. This suggests that NXN may be a useful biomarker for the assessment of the effectiveness of drugs that target histone H3.

In conclusion, NXN is a protein that plays a critical role in the regulation of DNA replication, repair, and metabolism. It is also involved in the regulation of cell cycle progression and has been shown to interact with a number of proteins, including p53 and histone H3. As a result, NXN has become an attractive drug target for researchers and may be a useful biomarker for the assessment of the effectiveness of drugs that target these proteins.

Protein Name: Nucleoredoxin

Functions: Functions as a redox-dependent negative regulator of the Wnt signaling pathway, possibly by preventing ubiquitination of DVL3 by the BCR(KLHL12) complex. May also function as a transcriptional regulator act as a regulator of protein phosphatase 2A (PP2A) (By similarity)

The "NXN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NXN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets